In addition to antibodies, other types of immunotherapy drugs targeting B7H3 are also being investigated for the treatment of prostate cancer. The trial found that enoblituzumab was well-tolerated by patients and showed promising efficacy in shrinking tumors and delaying disease progression. ![]() For example, a phase 1 clinical trial tested an anti-B7H3 antibody called 8H9 in patients with advanced prostate cancer and found that the drug was well-tolerated and showed some evidence of clinical activity.Īnother clinical trial tested an anti-B7H3 antibody called enoblituzumab in patients with localized prostate cancer who were not eligible for surgery or radiation therapy. Several studies have investigated the use of B7H3-targeted immunotherapy drugs in prostate cancer. The combination of all these, injected into the cancer, is where the real success is found. It may be proven as or more important than current FDA-approved immunotherapy. ![]() We certainly have seen success in working with this checkpoint inhibitor in many cancer types. In many of the NanoString analyses we performed on patients during immunotherapy treatment, the upregulation of B7H3 was a significant resistance mechanism. ![]() This is an area of great interest for me.
0 Comments
Leave a Reply. |